These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16236895)

  • 1. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Hoeper MM; Kramm T; Wilkens H; Schulze C; Schäfers HJ; Welte T; Mayer E
    Chest; 2005 Oct; 128(4):2363-7. PubMed ID: 16236895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension.
    Bonderman D; Nowotny R; Skoro-Sajer N; Jakowitsch J; Adlbrecht C; Klepetko W; Lang IM
    Chest; 2005 Oct; 128(4):2599-603. PubMed ID: 16236930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
    Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan therapy for chronic thromboembolic pulmonary hypertension. A national open label study assessing the effect of Bosentan on haemodynamics, exercise capacity, quality of life, safety and tolerability in patients with chronic thromboembolic pulmonary hypertension (BOCTEPH-Study).
    Ulrich S; Speich R; Domenighetti G; Geiser T; Aubert JD; Rochat T; Huber L; Treder U; Fischler M
    Swiss Med Wkly; 2007 Oct; 137(41-42):573-80. PubMed ID: 17990150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2.
    Hirashiki A; Adachi S; Nakano Y; Kono Y; Shimazu S; Shimizu S; Morimoto R; Okumura T; Takeshita K; Yamada S; Murohara T; Kondo T
    Life Sci; 2014 Nov; 118(2):397-403. PubMed ID: 24641953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses.
    Karavolias GK; Georgiadou P; Gkouziouta A; Kariofillis P; Karabela G; Tsiapras D; Sbarouni E; Chaidaroglou A; Degiannis D; Adamopoulos S; Voudris V
    Expert Opin Ther Targets; 2010 Dec; 14(12):1283-9. PubMed ID: 20958219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
    Hughes RJ; Jais X; Bonderman D; Suntharalingam J; Humbert M; Lang I; Simonneau G; Pepke-Zaba J
    Eur Respir J; 2006 Jul; 28(1):138-43. PubMed ID: 16611652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan therapy for portopulmonary hypertension.
    Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
    Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bosentan for patients with chronic thromboembolic pulmonary hypertension.
    Vassallo FG; Kodric M; Scarduelli C; Harari S; Potena A; Scarda A; Piattella M; Cassandro R; Confalonieri M
    Eur J Intern Med; 2009 Jan; 20(1):24-9. PubMed ID: 19237088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.
    Galiè N; Beghetti M; Gatzoulis MA; Granton J; Berger RM; Lauer A; Chiossi E; Landzberg M;
    Circulation; 2006 Jul; 114(1):48-54. PubMed ID: 16801459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; Surie S; Kloek JJ; Tan HL; Tepaske R; Fedullo PF; Bresser P
    J Thorac Cardiovasc Surg; 2010 Jan; 139(1):85-91. PubMed ID: 19660388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
    Becattini C; Manina G; Busti C; Gennarini S; Agnelli G
    Thromb Res; 2010 Jul; 126(1):e51-6. PubMed ID: 20172593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factor Profiles Achieved with Medical Therapy in Prevalent Patients with Pulmonary Arterial and Distal Chronic Thromboembolic Pulmonary Hypertension.
    Bartenstein P; Saxer S; Appenzeller P; Lichtblau M; Schwarz EI; Ulrich S
    Respiration; 2018; 96(2):127-137. PubMed ID: 29642071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
    McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
    Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta-analysis.
    Chen X; Zhai Z; Huang K; Xie W; Wan J; Wang C
    Clin Respir J; 2018 Jun; 12(6):2065-2074. PubMed ID: 29393580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.